FCMT
PFE icon

Founders Capital Management (Texas)’s Pfizer PFE Stock Holding History

Founders Capital Management (Texas)’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
13,473
+909
+7% +$23.8K 0.14% 47
2026
Q1 		$353K Buy
12,564
+312
+3% +$8.31K 0.17% 44
2025
Q4 		$305K Sell
12,252
-2,548
-17% -$64.3K 0.16% 49
2025
Q3 		$377K Buy
14,800
+95
+0.6% +$2.35K 0.2% 42
2025
Q2 		$356K Sell
14,705
-2,008
-12% -$46.8K 0.21% 40
2025
Q1 		$423K Sell
16,713
-5,444
-25% -$142K 0.27% 38
2024
Q4 		$588K Sell
22,157
-3,180
-13% -$86.3K 0.37% 32
2024
Q3 		$733K Buy
25,337
+480
+2% +$14K 0.45% 27
2024
Q2 		$696K Sell
24,857
-2,197
-8% -$60.5K 0.45% 28
2024
Q1 		$751K Sell
27,054
-6,979
-21% -$194K 0.51% 27
2023
Q4 		$980K Sell
34,033
-25,834
-43% -$781K 0.71% 27
2023
Q3 		$1.99M Sell
59,867
-2,144
-3% -$75.8K 1.52% 24
2023
Q2 		$2.27M Sell
62,011
-808
-1% -$31.4K 1.65% 22
2023
Q1 		$2.56M Buy
62,819
+550
+0.9% +$23.8K 1.96% 17
2022
Q4 		$3.19M Buy
62,269
+36
+0.1% +$1.73K 2.4% 17
2022
Q3 		$2.72M Sell
62,233
-784
-1% -$38.1K 2.22% 16
2022
Q2 		$3.3M Sell
63,017
-4,946
-7% -$252K 2.6% 14
2022
Q1 		$4.01M Hold
67,963
– – 2.57% 14
2021
Q4 		$4.01M Sell
67,963
-249
-0.4% -$12.3K 2.57% 14
2021
Q3 		$2.93M Sell
68,212
-25,251
-27% -$1.12M 2.01% 20
2021
Q2 		$3.66M Sell
93,463
-702
-0.7% -$27.3K 2.39% 17
2021
Q1 		$3.41M Sell
94,165
-5,326
-5% -$189K 2.43% 19
2020
Q4 		$3.66M Buy
+99,491
New +$3.65M 2.59% 12
2020
Q1 		$3.52M Sell
113,622
-7,190
-6% -$245K 3.65% 8
2019
Q4 		$4.49M Buy
120,812
+9,363
+8% +$334K 3.4% 8
2019
Q3 		$3.8M Buy
111,449
+26,775
+32% +$974K 3.04% 10
2019
Q2 		$3.48M Sell
84,674
-302
-0.4% -$12K 3.07% 10
2019
Q1 		$3.42M Sell
84,976
-221
-0.3% -$8.85K 3.21% 11
2018
Q4 		$3.53M Buy
85,197
+401
+0.5% +$16.6K 3.77% 7
2018
Q3 		$3.55M Buy
84,796
+23,622
+39% +$909K 2.92% 9
2018
Q2 		$2.11M Buy
61,174
+3,593
+6% +$123K 1.85% 23
2018
Q1 		$1.94M Buy
57,581
+643
+1% +$22.1K 1.63% 26
2017
Q4 		$1.96M Buy
56,938
+664
+1% +$22.6K 1.62% 24
2017
Q3 		$1.91M Sell
56,274
-179
-0.3% -$5.75K 1.58% 26
2017
Q2 		$1.8M Buy
56,453
+500
+0.9% +$15.8K 1.59% 26
2017
Q1 		$1.82M Buy
+55,953
New +$1.76M 1.63% 26

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return

Founders Capital Management (Texas)'s PFE Position: Q2 2026 in Review

Founders Capital Management (Texas) increased its Pfizer (PFE) stake by 7.2% in Q2 2026, buying an estimated $23.8K and bringing the position to 13,473 shares worth $324K. The position accounts for 0.14% of the portfolio, ranked #47.

Founders Capital Management (Texas) first reported a position in PFE in Q1 2017 and has held it in 36 quarters since. The position peaked at $4.49M in Q4 2019. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Founders Capital Management (Texas) held 13,473 shares of Pfizer worth $324K as of Q2 2026.
  • Founders Capital Management (Texas) bought 909 Pfizer shares in Q2 2026, an estimated $23.8K.
  • Pfizer made up 0.14% of Founders Capital Management (Texas)'s portfolio in Q2 2026, its #47 holding.
  • Founders Capital Management (Texas) first reported a position in Pfizer in Q1 2017 and has held it in 36 quarters since.
  • Founders Capital Management (Texas)'s Pfizer position peaked at $4.49M in Q4 2019.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.